Puma is a consultant radiation oncologist at Westmead Hospital, A/Prof at The University of Sydney and graduate of the Australian Institute of Company Directors. Her clinical and research specialities are head and neck, skin, lower gastrointestinal and haematological malignancies. Puma has served on the TROG Scientific Committee, Publications Committee (chair), RANZR Radiation Oncology Research Committee and Cancer Symptom Control Trials group’s Management Advisory Committee, and is currently chair of the Board of Head and Neck Cancer Australia. She is Facilitator of the annual RANZCR / TROG SMART workshop and the ACORD concept /protocol development workshops.
Hien serves as a consultant radiation oncologist at the Royal Adelaide Hospital, holding the position of Head of Research. Additionally, he provides patient care at the ICON cancer centre. He currently leads as the chairperson for the TROG Scientific Committee and is a council member of the RANZCR Faculty of Radiation Oncology. Hien’s expertise lies in leveraging advanced technologies within both clinical practice and research, which is crucial given the rapid advancements in radiation oncology. Collaborating with the South Australian team, Hien has dedicated several years to establishing the region’s inaugural particle therapy facility.
Georgia is a senior research fellow at Curtin School of Nursing, Curtin University, and is Co-Lead for the Cancer Domain in the Curtin Medical Research Institute. Her current research program is focused on patients and carers psychosocial and information needs, cancer survivorship and research into radiation therapy.
Georgia is a Board member for COGNO (Cooperative Trials Group for Neuro-Oncology). In joining the TROG Board she aims to help increase radiation therapists involvement in leading and conducting research.
Melissa is a radiation oncologist practicing in Christchurch, having completed her RANZCR fellowship training in Australia (Prince of Wales Hospital, Sydney) and New Zealand. She has an interest in radiation treatment for brain, breast and skin cancers. Melissa has been involved in recruiting patients to TROG trials since she was a registrar and has been an active member of the TROG urology and breast working parties.
Andrew is an experienced in-house lawyer and is currently Chief Legal Officer at Pacific National, Australia’s largest private rail freight operator. Andrew is energised by working with people, improving processes and generating valuable outcomes. He enjoys seeing solutions developed which achieve results within the right risk profiles. Andrew hopes to make a valuable contribution to TROG Cancer Research, to further cement TROG’s position as a world leading cancer research organisation and achieve its strategic objectives. He is current Chair of the Finance Audit & Risk Management Committee.
Sue is an experienced international executive in the pharmaceutical industry. She has worked in research as a health economist and in outcomes research in various cancers, and currently consults to the pharmaceutical industry. Sue has previously held Board positions internationally and is passionate about quality care for cancer patients. She is a current member of the Finance Audit & Risk Management Committee.
Dr Tuan Ha is a consultant Radiation Oncologist. He is a senior lecturer, mentor and examiner for The University of Queensland – School of Medicine and is involved in the development of radiation treatment protocols with EVIQ. His specific interest is in the treatment of breast, genitourinary and brain cancers, and a passion for rural and regional access to oncology. As Dean of RANZCR, Dr Ha’s role on the Board will continue to strengthen RANZCR’s collaboration with TROG Cancer Research.
Murray is a Deputy Chair of Cancer Voices NSW and Deputy Chair of the Health Consumer NSW Board. He has previously volunteered with Cancer Council NSW, drawing on his professional life experience in the NSW public sector around policy and advocacy. His personal cancer experiences include the death of his long term partner from pancreatic cancer in 2007, and successful surgical intervention for prostate cancer in 2009.
Associate Professor Nick Hardcastle is Radiation Oncology Medical Physicist and Physical Sciences Research Lead at Peter MacCallum Cancer Centre and a recognised leader in radiation oncology physics and clinical trial innovation. Within TROG Cancer Research, he chairs the New Techniques and Technologies Committee, providing strategic leadership on the evaluation and integration of emerging radiation therapy technologies. Through his governance contributions, technical expertise and collaborative leadership, Nick has helped strengthen radiation therapy quality assurance across the TROG network, helping position TROG and the broader radiation oncology community at the forefront of high-quality clinical research.
Dr Gerry Adams is an experienced radiation oncologist and respected professional leader who brings valuable clinical, governance and policy expertise to the TROG Board. He has made a significant contribution to regional radiation oncology, has served as Dean of the Faculty of Radiation Oncology at RANZCR, and currently chairs RANZCR’s Māori, Aboriginal and Torres Strait Islander Empowerment Committee (MATEC). Gerry offers a collaborative and practical leadership style, together with a strong commitment to equity, workforce development and improved access to high-quality cancer care.
